Raising capital: A new playbook for a new era in biotech

In a market suppressed by inflation, how can the biotech industry continue to raise essential capital for innovation? The latest episode of Pathfinders in Biopharma brought together some of biotech’s foremost venture capitalists to consider the sector’s future, chaired by RBC’s Noël Brown, Head of U.S. Biotechnology Investment Banking.

PlayWatch video

By Noël Brown
Published | 36 min read

Key points

  • In a tough biotech market, investors are favoring mid- to late-stage clinical companies, while early-stage ventures struggle for funds.
  • There has been a broadening of interest away from certain modalities and toward emerging fields and exciting new targets offering promising innovation.
  • Businesses still need to find the right balance between advancing its entire pipeline and focusing on a single lead program.
  • Creative deal structures, such as tranched investments tied to agreed upon milestones, are re-emerging.
  • Pharma is increasingly filling the funding gap, buying or investing in biotechs as a way of outsourcing innovation.

Our experts

Noël Brown

 

Stay informed

Get the latest insights and news from RBC Capital Markets delivered to your inbox.